![Billing & Coding: MAAA Coding 101](https://www.g2intelligence.com/wp-content/uploads/2022/11/Dec22.LCA_.DV_.MAAACodes-iStock-1800x1250-1-1080x675.jpg)
Billing & Coding: MAAA Coding 101
What labs and billing managers need to know about multianalyte assays with algorithmic analyses coding for tests based on molecular platforms.
What labs and billing managers need to know about multianalyte assays with algorithmic analyses coding for tests based on molecular platforms.
The FDA recently confirmed that a new rule requiring healthcare providers to notify patients of their breast density status will be released in late 2022 or early 2023.
FDA confirms the new rule, which will update the Mammography Quality Standards Act, will publish before the end of 2022, or early 2023.
Though there were fewer new approvals last month, the impact of the products that did gain approval more than made up for the drop in volume.
Recent case shows that fraud and kickback schemes involving CGx testing continue to be on the federal enforcement radar.